Under the terms of the agreement, Penwest will receive undisclosed fees and payments.
Jennifer Good, president and CEO of Penwest, said: “These arrangements fit with our strategy of leveraging the value of our proprietary drug delivery technologies to provide additional financial benefit to Penwest while permitting us to focus our internal resources on building our own product pipeline.”